At the 2020 edition of Uppsala Monitoring Centre’s cutting-edge research conference, we’ll be making the case for evidence of impact.
In 2018, we celebrated the 50th birthday of the WHO Programme for International Drug Monitoring and the 40th of Uppsala Monitoring Centre. Many people have worked very hard over all these years and we see progress: the programme now counts more than 130 contributing countries and over 20 million reports are available in VigiBase, the global database for individual case safety reports. Many safety issues have been identified and risk minimisation measures taken, and regulatory systems are being strengthened all over the world.
The scope of pharmacovigilance has expanded to also include medication errors, substandard and falsified medicines, medicated devices and rational use of medicines. Moreover, many more stakeholders are reporting unwanted effects of treatments, thus sharing different perspectives and perceptions on safety.
But are we making an impact? Are we achieving our vision of a wiser use of medicines and safer patients? And how do we know whether we are on the right path? These are questions we will discuss at Uppsala Forum: Putting pharmacovigilance on trial, on 28-29 May 2020.
More information will follow, and invitations will be sent out during the latter half of 2019.
In 2018, Uppsala Forum was replaced by UMC’s 40th Anniversary conference, where key actors from the past and present of the WHO Programme for International Drug Monitoring joined pharmacovigilance colleagues to reflect on the progress pharmacovigilance has made since the programme’s inception in 1968.
The need to develop and rapidly deploy new treatments tests the limits of traditional pharmacovigilance and demands new thinking and practice. How can we ensure the safety of patients using new drugs when rapid access is of paramount importance?
Topics covered included: Patient groups at risk – genotypes and phenotypes; Structure analysis of medicinal products; Detection and confirmation of signals; Individualized benefit-risk assessment; Effective communication to health professionals and patients in clinical settings.
Causality assessment plays a critical part in the search for better science and safer use of medicines. Although the principles of causality assessment is straightforward, the application of those principles to an individual case is a philosophical as well as scientific challenge.